Hydrocephalus – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:19 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hydrocephalus – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Water Absorption in the Brain for Adults with Hydrocephalus Using O15-Water https://clinicaltrials.eu/trial/study-on-water-absorption-in-the-brain-for-adults-with-hydrocephalus-using-o15-water/ Wed, 29 Apr 2026 15:04:05 +0000 https://clinicaltrials.eu/trial/study-on-water-absorption-in-the-brain-for-adults-with-hydrocephalus-using-o15-water/ This clinical trial is focused on studying hydrocephalus, a condition where there is an accumulation of fluid in the brain, leading to increased pressure. The study will use a treatment involving O15-WATER, also known as Oxygen-15 Water or MT-100, which is a solution for injection. This treatment will be administered directly into the brain’s ventricles, which are fluid-filled spaces, to assess how well the brain absorbs water in individuals with hydrocephalus.

The purpose of the study is to establish quantitative measures of how the brain absorbs water in patients with hydrocephalus. The study will involve a procedure where O15-WATER is infused into the brain, and the absorption will be measured using imaging techniques like PET/CT, which stands for Positron Emission Tomography and Computed Tomography. This will help researchers understand the water absorption capacity in patients with both communicating and non-communicating types of hydrocephalus.

Participants in the study will undergo the infusion and imaging process to gather data on how their brain handles the injected water. The study aims to develop a model of water absorption in the brain, which could provide valuable insights into the treatment and management of hydrocephalus. The trial is being conducted by Oslo University Hospital and is expected to continue until the end of 2026.

]]> Study of Gadobutrol for MRI in Adults with Cerebrospinal Fluid Disorders, Including Hydrocephalus and Brain Tumors https://clinicaltrials.eu/trial/study-of-gadobutrol-for-mri-in-adults-with-cerebrospinal-fluid-disorders-including-hydrocephalus-and-brain-tumors/ Wed, 29 Apr 2026 15:02:48 +0000 https://clinicaltrials.eu/trial/study-of-gadobutrol-for-mri-in-adults-with-cerebrospinal-fluid-disorders-including-hydrocephalus-and-brain-tumors/ This clinical trial is focused on studying several conditions related to the brain and spinal fluid, including communicating hydrocephalus, primary malignant brain tumor, intracranial cysts, Chiari malformation, idiopathic intracranial hypotension, idiopathic intracranial hypertension, and conditions following a subarachnoid hemorrhage. The study uses a special type of MRI (magnetic resonance imaging) contrast agent called gadobutrol, which is a gadolinium-based contrast agent (GBCA). This agent is administered into the spinal canal to help visualize the flow and clearance of fluids in the brain.

The purpose of the study is to better understand how the contrast agent moves within the brain. This helps in assessing where there might be blockages in the flow of cerebrospinal fluid and how quickly substances are cleared from the brain. Participants will receive the contrast agent through a procedure called intrathecal use, which means it is injected into the space around the spinal cord. After the injection, MRI scans will be performed to track the distribution and intensity of the contrast agent over time.

The study aims to provide valuable insights into the treatment and management of these brain and spinal fluid conditions by observing changes in the MRI signal after the contrast is administered. This information could potentially lead to improved diagnostic and therapeutic strategies for patients with these conditions.

]]>